The company is in the business of building value, which it is doing. The day to day stock price, which they are aware of, is not something they are in the business of propping up for the sake of retail peace-of-mind. At some point, they will release Rett data. Then they will provide AD data. They will start new trials. They will file applications for approval. They will engage channel partners. In aggregate, these things will build value and the stock price will respond.